Anton Egorov

1.5k total citations · 1 hit paper
25 papers, 260 citations indexed

About

Anton Egorov is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Anton Egorov has authored 25 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Anton Egorov's work include HER2/EGFR in Cancer Research (11 papers), Cancer Treatment and Pharmacology (11 papers) and Breast Cancer Treatment Studies (9 papers). Anton Egorov is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Cancer Treatment and Pharmacology (11 papers) and Breast Cancer Treatment Studies (9 papers). Anton Egorov collaborates with scholars based in France, United States and Spain. Anton Egorov's co-authors include Javier Cortés, Shahid Ashfaque, Wěi Li, Sung‐Bae Kim, Jack W. Singer, Giuliano Santos Borges, Fabrice André, Ruth Pettengell, Sara A. Hurvitz and Seock‐Ah Im and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Anton Egorov

23 papers receiving 255 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

2024 53 citations Javier Cortés, Sara A. Hurvitz et al. Nature Medicine profile →

Peers

Countries citing papers authored by Anton Egorov

Since Specialization

Citations

This map shows the geographic impact of Anton Egorov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anton Egorov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anton Egorov more than expected).

Fields of papers citing papers by Anton Egorov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anton Egorov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anton Egorov. The network helps show where Anton Egorov may publish in the future.

Co-authorship network of co-authors of Anton Egorov

This figure shows the co-authorship network connecting the top 25 collaborators of Anton Egorov. A scholar is included among the top collaborators of Anton Egorov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anton Egorov. Anton Egorov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03 2025 ·Annals of Oncology ·Cristina Saura, Javier Cortés, Shanu Modi, S.-B. Kim, E.P. Hamilton, (unknown), Ian E. Krop, (unknown), (unknown), S-A. Im, Pia Herbolsheimer, Maha Karnoub, Aislyn Boran, (unknown), Anton Egorov, Fabrice André	0
2	Abstract PS8-03: Exploratory biomarker analysis of Trastuzumab deruxtecan (T-DXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03) 2025 ·Clinical Cancer Research ·William Jacot, Seock‐Ah Im, Sherene Loi, Thomas Bachelot, (unknown), Srinivasan Madhusudan, Hiroji Iwata, Giuseppe Curigliano, (unknown), Anton Egorov, Vinit Kumar, Aislyn Boran, Yusuke Kuwahara, Erika Hamilton	2
3	322P Human epidermal growth factor receptor 2 (HER2)-directed therapies administered after trastuzumab deruxtecan (T-DXd) remain effective in patients (pts) with metastatic breast cancer (mBC): Exploratory analysis from DESTINY-Breast02 and -03 2025 ·ESMO Open ·(unknown), Giampaolo Bianchini, Eva Ciruelos, (unknown), G. Curigliano, (unknown), (unknown), (unknown), S-A. Im, Hiroaki Iwata, (unknown), (unknown), Wenjun Lü, (unknown), Anton Egorov, IE Krop	3
4	Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. 2024 ·Journal of Clinical Oncology ·Erika Hamilton, Sara A. Hurvitz, Seock‐Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung‐Bae Kim, (unknown), José Luiz Pedrini, Wěi Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano Santos Borges, Xian Wang, Thomas Bachelot, (unknown), Shahid Ashfaque, (unknown), Anton Egorov, Javier Cortés	5
5	Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial breakdown → 2024 ·Nature Medicine ·Javier Cortés, Sara A. Hurvitz, Seock‐Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung‐Bae Kim, Joanne Chiu, (unknown), Wěi Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano Santos Borges, Xian Wang, Thomas Bachelot, (unknown), Shahid Ashfaque, (unknown), Anton Egorov, Erika Hamilton	53
6	A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases 2024 ·Annals of Oncology ·Fabrice André, Javier Cortés, (unknown), (unknown), Wěi Li, Y.H. Park, (unknown), S.-B. Kim, Toshinari Yamashita, José Luiz Pedrini, (unknown), L-M Tseng, (unknown), Ian E. Krop, (unknown), Kristen M. Tecson, Shahid Ashfaque, Anton Egorov, (unknown)	15
7	Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03. 2024 ·Journal of Clinical Oncology ·Cristina Saura, (unknown), Shanu Modi, Sung‐Bae Kim, Erika Hamilton, Sara A. Hurvitz, Ian E. Krop, Giuseppe Curigliano, Hiroji Iwata, Seock‐Ah Im, Pia Herbolsheimer, Maha Karnoub, Dhiraj Gambhire, Anton Egorov, Fabrice André	0
8	Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial 2024 ·The Lancet Oncology ·Tanja Fehm, Francesco Cottone, (unknown), Fabrice André, Ian E. Krop, Yeon Hee Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruíz Borrego, Rinat Yerushalmi, François P. Duhoux, Toshimi Takano, (unknown), Anton Egorov, Sung‐Bae Kim	16
9	Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer 2024 ·Cancer Science ·Hiroji Iwata, Binghe Xu, Sung‐Bae Kim, Wei‐Pang Chung, Winnie Yeo, Min Hwan Kim, Ling‐Ming Tseng, (unknown), Chiun‐Sheng Huang, Jee Hyun Kim, Joanne Chiu, Toshinari Yamashita, Wei Li, Anton Egorov, (unknown), (unknown), Yuji Nishiyama, Masahiro Sugihara, Javier Cortés, Seock‐Ah Im	6
10	186O Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2–positive (HER2+) metastatic breast cancer (mBC) 2023 ·ESMO Open ·Tanja Fehm, (unknown), (unknown), Fabrice André, Ian E. Krop, Y.H. Park, Michelino De Laurentiis, Yasuo Miyoshi, Anne Armstrong, Manuel Ruíz Borrego, Rinat Yerushalmi, François P. Duhoux, Toshimi Takano, Wenjun Lü, (unknown), Anton Egorov, S-B. Kim	4
11	377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03 2023 ·Annals of Oncology ·(unknown), Shanu Modi, Wěi Li, Y.H. Park, Wei‐Pang Chung, S-B. Kim, Javier Cortés, Toshinari Yamashita, José Luiz Pedrini, S-A. Im, L-M Tseng, Nadia Harbeck, (unknown), G. Curigliano, E. Mathias, Jillian Cathcart, (unknown), Shahid Ashfaque, Anton Egorov, Fabrice André	24
12	Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02 2023 ·Cancer Research ·Ian E. Krop, (unknown), Sung‐Bae Kim, Giuliano Santos Borges, Sercan Aksoy, Joaquín Gavilá Gregori, Rebecca Roylance, Elgene Lim, Rinat Yerushalmi, Flora Zagouri, François P. Duhoux, Tanja Fehm, Toshimi Takano, Anton Egorov, (unknown), Jillian Cathcart, (unknown), Fabrice André	14
13	An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03. 2023 ·Journal of Clinical Oncology ·Ian E. Krop, Hans Wildiers, Sara A. Hurvitz, Javier Cortés, Seock‐Ah Im, Hiroji Iwata, Fabrice André, Cristina Saura, Shanu Modi, Sung‐Bae Kim, Anton Egorov, (unknown), Jillian Cathcart, (unknown), Yingkai Cheng, Yeon Hee Park	7
14	First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study 2022 ·British Journal of Cancer ·Eric Van Cutsem, Iwona Danielewicz, Mark Saunders, Per Pfeiffer, Guillem Argilés, Christophe Borg, Rob Glynne‐Jones, Cornelis J.A. Punt, Agnès J. van de Wouw, М. Yu. Fedyanin, Daniil Stroyakovskiy, Hendrik Kroening, Pilar García‐Alfonso, Harpreet Wasan, Alfredo Falcone, Ronan Fougeray, Anton Egorov, Nadia Amellal, Vladimir Moiseyenko	9
15	236P Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) 2022 ·Annals of Oncology ·Javier Cortés, (unknown), Hitoshi Iwata, E.P. Hamilton, (unknown), Anton Egorov, Jillian Cathcart, (unknown), Emarjola Bako, (unknown)	1
16	Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study 2020 ·Annals of Oncology ·Eric Van Cutsem, Iwona Danielewicz, Mark Saunders, Per Pfeiffer, Guillem Argilés, Christophe Borg, Rob Glynne‐Jones, Cornelis J.A. Punt, Agnès J. van de Wouw, М. Yu. Fedyanin, Daniil Stroyakovskiy, Hendrik Kroening, Pilar García‐Alfonso, Harpreet Wasan, Alfredo Falcone, (unknown), Anton Egorov, (unknown), Nadia Amellal, В. Моисеенко	40
17	Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B‐cell non‐Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306) 2019 ·British Journal of Haematology ·Ruth Pettengell, Monika Długosz‐Danecka, David Andorsky, David Belada, Pencho Georgiev, Donald P. Quick, Jack W. Singer, (unknown), Athanasios Pallis, Anton Egorov, Gilles Salles	12
18	Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial 2018 ·Clinical Drug Investigation ·Ruth Pettengell, Bertrand Coiffier, Anton Egorov, Jack W. Singer, (unknown)	14
19	Results of a Phase 3 Randomised Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Not Eligible for Stem Cell Transplantation 2018 ·Blood ·Gilles Salles, Wojciech Jurczak, David Andorsky, Donald P. Quick, Jack W. Singer, (unknown), Lixia Wang, Anton Egorov, (unknown), Ruth Pettengell	3
20	[Double-blind placebo-controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis]. 2005 ·PubMed ·А.В. Сивков, (unknown), Anton Egorov	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact